| PF-ILD (n = 14,413) |
---|
Mean, € (SD) | Median, € (IQR) |
---|
Cost per patient | 43,807 (57,904) | 25,613 (10,622–54,287) |
Annual cost per patient | 81,286 (21,935) | 18,362 (6,856–52,026) |
- End of follow-up was defined as the earliest of patient death, end of study period (31 December 2017) or last available record (hospitalisation, consultation or healthcare reimbursement) in the data source. Patients with a data gap persisting beyond 12 months are considered to have their follow-up ceased at their last record. Costs were based on non-hospital medical procedures (CCAM). Respiratory tests performed during a hospital stay were not taken into account contrary to indicators
- CCAM classification commune des actes médicaux [medical classification for clinical procedures], IQR interquartile range, PF-ILD progressive fibrosing interstitial lung disease, SD standard deviation